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Background. Infective endocarditis (IE) mostly occurs after spontaneous low-grade bacteremia. Thus, IE cannot
be prevented by circumstantial antibiotic prophylaxis. Platelet activation following bacterial-ﬁbrinogen interaction or
thrombin-mediated ﬁbrinogen-ﬁbrin polymerization is a critical step in vegetation formation. We tested the efﬁcacy
of antiplatelet and antithrombin to prevent experimental IE.
Methods. A rat model of experimental IE following prolonged low-grade bacteremia mimicking smoldering bac-
teremia in humans was used. Prophylaxis with antiplatelets (aspirin, ticlopidine [alone or in combination], eptiﬁba-
tide, or abciximab) or anticoagulants (antithrombin dabigatran etexilate or anti–vitamin K acenocoumarol) was
started 2 days before inoculation with Streptococcus gordonii or Staphylococcus aureus. Valve infection was assessed
24 hours later.
Results. Aspirin plus ticlopidine, as well as abciximab, protected 45%–88% of animals against S. gordonii and
S. aureus IE (P < .05). Dabigatran etexilate protected 75% of rats against IE due to S. aureus (P < .005) but failed to
protect against S. gordonii (<30% protection). Acenocoumarol was ineffective.
Conclusions. Antiplatelet and direct antithrombin agents may be useful in the prophylaxis of IE in humans. In
particular, the potential dual beneﬁt of dabigatran etexilate might be reconsidered for patients with prosthetic valves,
who require life-long anticoagulation and in whom S. aureus IE is associated with high mortality.
Keywords. experimental endocarditis; prophylaxis; antiplatelets; anticoagulants; Staphylococcus aureus;
Streptococcus gordonii.
Infective endocarditis (IE) is eventually lethal if not
aggressively treated with antibiotics alone or in combi-
nation with surgery. Therefore, it should be prevented
when possible. Over the last 50 years, guidelines for
the prevention of IE advocated the use of antibiotics
for at-risk patients undergoing dental surgery or other
medico-surgical procedures that might induce bactere-
mia [1]. These guidelines were based on the fact that the
leading causes of IE were oral streptococci and skin col-
onizers (eg, Staphylococcus species), which may invade
the bloodstream [2].
Since the 1990s, however, the efﬁcacy of antibiotic IE
prophylaxis has been challenged by case-control studies
[3, 4] that indicated that IE occurs independently of
medico-surgical procedures and receipt of antibiotic
prophylaxis. Thus, this low circumstantial correlation
between dental procedures and IE indicates that IE
is more likely to result from spontaneous bouts of
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bacteremia occurring during normal day-to-day activities. This
assumption was further supported by the fact that the cumula-
tive numbers of bacteria circulating in the blood during chewing
or toothbrushing are vastly superior (by 105–6 times) than the
numbers resulting from punctual dental procedures [5, 6].
On this basis, the American Heart Association and the Euro-
pean Society for Cardiology have revisited their guidelines for
IE prophylaxis and drastically decreased the indications for pro-
phylactic antibiotic use [7, 8]. However, while restricting the
spectrum of antibiotic prophylaxis, the new guidelines do not
propose any alternatives to prevent IE caused by the numerous
occurrences of spontaneous bacteremia.
Because IE is life-threatening and difﬁcult to treat, general
protective strategies are desired for high-risk patients [3, 9].
Such measures should be compatible with chronic use and
based on validated physiopathological concepts. Here we tested
the hypothesis that interfering with bacteria-induced platelet
aggregation or prothrombin activation could ﬁt this purpose.
The logic of this approach was based on the fact that bacteria
capable of interacting with platelets are more prone to induce
IE [10].
Most cases of IE are due to oral streptococci (eg, Streptococ-
cus gordonii) or Staphylococcus aureus [2].We tested several an-
tiplatelet and anticoagulant drugs for their efﬁcacy in the
prophylaxis of experimental IE induced by S. gordonii and
S. aureus. Antiplatelet drugs included aspirin, ticlopidine, epti-
ﬁbatide, and abciximab. Aspirin inhibits platelet cyclooxy-
genase 1 (COX1) activity, thereby blocking thromboxane A2
(TXA2), resulting in a reduction of platelet activation. Ticlopi-
dine inhibits the platelet ADP receptor, P2Y12, thereby sup-
pressing ADP-induced platelet activation and aggregation.
Both TXA2 and ADP are major agonists of platelet activation.
Eptiﬁbatide and abciximab act by antagonizing the GP IIb/
IIIa receptor for ﬁbrinogen on the platelet surface. These
drugs block platelet aggregation by preventing the binding of
ﬁbrinogen molecules that cross-link adjacent platelets [11]. An-
ticoagulants included dabigatran etexilate and acenocoumarol.
Dabigatran etexilate competitively binds to the active site of
thrombin, preventing the conversion of soluble ﬁbrinogen to
insoluble ﬁbrin and subsequent clot formation. Acenocoumarol
exhibited its anticoagulant effect by inhibition of vitamin K
epoxide reductase, ultimately leading to the depletion of func-
tional vitamin K–dependent clotting factors [12].
Bacteria were inoculated continuously at low concentrations
to simulate the constant exposure to spontaneous smoldering
bacteremia occurring most of the time in humans during
routine daily activities, in the case of oral streptococci [6], or
from more or less prolonged low-grade discharges from an in-
fected intravascular device, in the case of staphylococci [13].
The results indicate that interfering with platelet activation
is an effective way to prevent valve infection against these 2
pathogens.
MATERIALS AND METHODS
Ethics Statement
Blood specimens were obtained from one of the authors
(T. R. V.) under safe conditions. Ethical approval was not re-
quired. The animal studies were performed in strict accordance
with the recommendations of the Swiss Federal Act on Animal
Protection. All animal protocols were reviewed and approved by
the Cantonal Committee on Animal Experiments of the State of
Vaud (permit 879.8). A mixture of ketamine (75 mg/kg) and
midazolam (5 mg/kg) anesthesia was administered to animals
before any surgical procedure. During all animal experimenta-
tion procedures, all efforts were made to minimize the potential
for suffering.
Bacterial Strains and Growth Conditions
The well-described isolates of S. gordonii (strain Challis) and
coagulase-positive S. aureus (strain Newman) [14] were used.
S. gordonii was grown at 37°C with 5% CO2 in brain-heart
infusion broth (Difco; Becton Dickinson, Sparks, MD) and
S. aureus at 37°C in tryptic soy broth (Difco).
Antiplatelet and Anticoagulant Compounds
Antiplatelet drugs included aspirin (Aspegic, Sanoﬁ Aventis,
Meyrin/Genève, Switzerland), ticlopidine (Sigma-Aldrich,
Buchs, Switzerland), eptiﬁbatide (Integrilin, GlaxoSmithKline,
Münchenbuchsee, Switzerland), and abciximab (ReoPro, Eli
Lilly, Vernier/Genève, Switzerland). Anticoagulants included
dabigatran etexilate (Pradaxa, Boehringer Ingelheim, Basel,
Switzerland) and acenocoumarol (Sigma-Aldrich). Dabigatran,
the active form of dabigatran etexilate, was kindly provided by
Dr Peter Verhamme (Leuven, Belgium).
None of these agents possessed antimicrobial activity against
the bacterial test strains, as shown by minimal inhibitory con-
centrations of ≥128 µg/mL, far in excess of pharmacologically
relevant concentrations. Moreover, after 24 hours of exposure
of 106 colony-forming units (CFU)/mL of the organisms to
either 50 µg/mL of aspirin, 2.0 µg/mL of ticlopidine, 2.5 µg/
mL of eptiﬁbatide, 10 µg/mL of abciximab, 150 ng/mL of dabi-
gatran, or 2 µg/mL of acenocoumarol (ie, concentrations within
the therapeutic plasma levels in humans after standard doses
[15–20]), no effect on bacterial growth rates was observed.
Assessment of Drug Effect on Bacteria-Induced Platelet
Aggregation and Plasma Coagulation
Platelet-rich plasma (PRP) and platelet-poor plasma for plate-
let-aggregation tests were obtained from anticoagulated human
blood as described previously [21]. The extent of platelet aggre-
gation inhibition of aspirin, ticlopidine, aspirin plus ticlopidine,
eptiﬁbatide, and abciximab was performed by light transmis-
sion (A600 nm), using a ﬂuorometer Inﬁnite 200 Pro (Tecan,
Salzburg, Austria) [21]. Platelet aggregation was monitored
every minute for 20 minutes. The various inhibitors were
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compared with regard to the interval between the addition of
bacteria to the PRP suspension and the onset of the aggregation
response (lag time). The light transmission of PRP alone was
deﬁned as 0% aggregation. Platelet aggregation with ADP (10
µM) was used as a positive control. Three independent assays
were performed.
The anticoagulant effect of dabigatran etexilate and aceno-
coumarol was assessed by a modiﬁcation of the clotting time
test described by Cheng et al [22]. In brief, blood of control
rats and rats receiving anticoagulants as in in vivo prophylactic
experiments was drawn into plastic tubes without any anticoag-
ulant and allowed to clot. In some assays, S. gordonii, S. aureus,
or saline were added to the blood to test their possible interfer-
ence with coagulation. In these experiments, 500 µL of rat blood
was spiked with bacteria (ﬁnal concentration, 104 CFU/mL),
and tubes were observed until visible blood clotting appeared.
Rat Endocarditis Model and Prophylaxis Study
The production of catheter-induced aortic vegetations and the
installation of a permanent intravenous line connected to a pro-
grammable infusion-pump device were performed in female
Wistar rats, as described previously [14].
Prophylaxis began after the insertion of the intracardiac cath-
eter and lasted for 48 hours. Aspirin (8 mg/kg) and ticlopidine
(10 mg/kg), alone or in combination, were administered by an
intravenous bolus injection every 12 hours [15, 23]. Eptiﬁbatide
was administrated by a bolus of 180 µg/kg followed by a con-
tinuous infusion of 2 µg/kg/minute over 24 hours. Abciximab
was given every 12 hours by a bolus of 0.25 mg/kg followed
by a continuous infusion of 0.125 µg/kg/minute [24]. Dabiga-
tran etexilate prophylaxis was performed by intraperitoneal in-
jections of 5 or 10 mg/kg every 12 hours [25, 26]. Two different
doses were tested because dabigatran etexilate has been shown
to inhibit thrombin in a dose-dependent manner [26]. For in-
traperitoneal injections of dabigatran etexilate, commercially
available capsules of Pradaxa were dissolved as described [27].
Acenocoumarol was administrated in a subcutaneous injection
of 1 mg/kg once a day [20]. Stock solutions of acenocoumarol
(10 mg/mL) were prepared in dimethyl sulfoxide (Sigma-
Aldrich) and adjusted to the desired concentration in a 1:1
(vol/vol) ratio of saline to distilled water. The chosen doses
were previously used in animal models or in humans. Control
rats received saline. Pharmacokinetics analysis has not been
attempted.
Forty-eight hours after starting prophylaxis, animals were in-
oculated with 106 CFU of S. gordonii or 105 CFU of S. aureus.
The inocula were prepared by diluted overnight cultures until
the desired concentration and progressively delivered at a
pace of 0.0017 mL/minute over 10 hours [14]. Rats were eutha-
nized 24 hours after inoculation ended. The cardiac vegetations
were sterilely removed, weighed, and processed as described
elsewhere to determine the number of viable organisms [14].
Statistical Analysis
The quantiﬁcation of platelet aggregation inhibition (lag times),
clotting times, and the weights of the vegetations were expressed
as mean ± standard deviation (SD) and compared by the Stu-
dent t test. The percentage of infected vegetations was analyzed
by the Fisher exact test. All statistical analyses were performed
with GraphPad Prism software (version 4.0 for Windows;
GraphPad Software, La Jolla, CA; http://www.graphpad.com).
Differences were considered signiﬁcant at P values of <.05, by
use of 2-sided signiﬁcance levels.
RESULTS
Platelet Aggregation
One key question was the platelet aggregation phenotype in the
presence or absence of bacteria or antiaggregants. In the ab-
sence of either bacteria or drug, the lag time for spontaneous
platelet aggregation was >20 minutes, whereas ADP induced ag-
gregation within 1 minute. When S. gordonii and S. aureus
alone were added to platelets, the mean lag times (±SD) of plate-
let aggregation were 9.0 ± 0.6 minutes and 1.3 ± 0.7 minutes, re-
spectively, underlining the superior aggregation capacity of S.
aureus. In the presence of S. gordonii, all of the antiaggregants
prolonged the lag time of microbe-induced aggregation to >20
minutes (upper measurement limit). In the presence of S. aure-
us, aspirin alone, ticlopidine alone, or aspirin and ticlopidine in
combination signiﬁcantly increased the lag time (from 1 to ap-
proximately 5 minutes). With regard to GPIIb/IIIa inhibitors,
both eptiﬁbatide and abciximab completely inhibited S. aure-
us–induced platelet aggregation (no platelet aggregation was ob-
served within 20 minutes).
Prevention of Experimental IE Due to S. gordonii by
Inhibitors of Platelet Activation
The efﬁcacy of antiplatelet drugs to prevent experimental
S. gordonii IE is depicted in Figure 1. In control rats, the inci-
dence of valve infection was 78%. Compared with these control
values, aspirin or ticlopidine alone failed to prevent IE (87% and
80% of vegetations infected, respectively). In contrast, the com-
bination of aspirin and ticlopidine effectively prevented IE (21%
of vegetations infected; P = .0007).
Eptiﬁbatide failed to prevent IE (75% of vegetations infected),
whereas abciximab successfully prevented IE (15% of vegeta-
tions infected; P = .0003). Bleeding events were observed in 2
of 12 animals receiving eptiﬁbatide and in any animals receiving
aspirin-ticlopidine or abciximab.
Prevention of Experimental IE Due to S. aureus by
Inhibitors of Platelet Activation
Figure 2 depicts a similar experiment performed with S. aureus.
In control rats, the incidence of IE was 93%. Aspirin or ticlopi-
dine alone failed to prevent IE (100% and 83% vegetations
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infected, respectively). In contrast, aspirin combined with ticlo-
pidine had a marginal but signiﬁcant protective effect (55% of
vegetations infected; P = .04). Eptiﬁbatide failed completely
(100% of vegetations infected), yet bleeding events occurred
in 4 of 7 animals, indicating that the drug indeed affected plate-
let activity. In sharp contrast, abciximab was highly successful in
preventing IE (12% of vegetations infected; P = .0002), and no
bleeding events were observed.
Prevention of Experimental Endocarditis Due to S. gordonii
by Antithrombin and Anti–Vitamin K Agents
The results shown in Figure 1 and Figure 2 highlight the pro-
phylactic efﬁcacy of the anti-GPIIb/IIIa monoclonal antibody
abciximab. As abciximab is supposed to block the ﬁbrinogen-
ﬁbrin platelet interaction in the ﬁbrinogen-ﬁbrin platelet net-
work, we investigated whether interfering with the upstream
bacterial-ﬁbrinogen binding by use of dabigatran etexilate or
acenocoumarol would have the same effect. Dabigatran etexilate
at either 5 mg/kg or 10 mg/kg failed to prevent experimental S.
gordonii IE (100% and 70% of vegetations infected, respectively;
Figure 3). Bleeding events were observed in only 1 of 10 animals
with the 10 mg/kg dose. Likewise, acenocoumarol did not suc-
cessfully prevent IE (67% of vegetations infected), and bleeding
complications were observed in 2 of 6 animals. Both dabigatran
etexilate and acenocoumarol signiﬁcantly increased blood clot-
ting time both in the absence or the presence of S. gordonii
(Table 1), demonstrating that they were biologically active in
the animals.
Prevention of Experimental Endocarditis Due to S. aureus
by Antithrombin and Anti–Vitamin K Agents
Figure 4 shows the results of prophylaxis with S. aureus. At a
dose of 5 mg/kg, dabigatran etexilate signiﬁcantly decreased
the rate of IE (44% of vegetations infected; P = .028). There
was no bleeding observed at this dose. Since dabigatran etexilate
has a dose-dependent activity [26], we further tested its efﬁcacy
at 10 mg/kg. At this dose, dabigatran etexilate decreased the rate
of IE (25% of vegetations infected; P = .003), but bleeding events
were observed in 2 of 8 animals. In contrast, acenocoumarol
failed to prevent IE (100% of vegetations infected), and bleeding
events were observed in 4 of 10 animals.
The anticoagulant effect of these compounds in animals was
demonstrated by a signiﬁcant increase in the blood clotting time
both in the absence or presence of bacteria (Table 1).
DISCUSSION
In the present study, we observed a signiﬁcant protection
against experimental S. gordonii or S. aureus IE by drugs
Figure 2. Effect of prophylaxis with various antiplatelet agents on both
the weight of vegetations (upper panel) and the prevention of experimental
endocarditis (lower panel) due to Staphylococcus aureus. Data of vegeta-
tion weights are expressed as mean ± standard deviation. The numbers of
infected animals/total number of animals are indicated at the bottom of
each column. *P < .05, by the Student t test ( for vegetation weight) or
the Fisher exact test (for infected vegetations), compared with the control
group. Abbreviations: ABC, abciximab; ASA, aspirin; EPB, eptiﬁbatide; TCL,
ticlopidine.
Figure 1. Effect of prophylaxis with various antiplatelet agents on both
the weight of vegetations (upper panel) and the prevention of experimental
endocarditis (lower panel) due to Streptococcus gordonii. Data of vegeta-
tion weights are expressed as mean ± standard deviation. The numbers of
infected animals/total number of animals are indicated at the bottom of
each column. *P < .001, by the Student t test (for vegetation weight) or
the Fisher exact test (for infected vegetations), compared with the control
group. Abbreviations: ABC, abciximab; ASA, aspirin; EPB, eptiﬁbatide; TCL,
ticlopidine.
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interfering with platelet activation/aggregation, including the
combination of aspirin plus ticlopidine, abciximab, and the an-
tithrombin dabigatran etexilate.
Aspirin (a COX1 inhibitor) and ticlopidine (an ADP receptor
P2Y12 inhibitor) block the effector signal transduction leading
to platelet activation and aggregation [11]. This blockage occurs
downstream of the activator signals transmitted by interactions
of S. gordonii or S. aureus with the agonist platelet receptors
GPIb, GPVI, or GPIIb/IIIa [28]. Thus, aspirin and ticlopidine
nonspeciﬁcally prevented platelet activation/aggregation against
both organisms by disrupting the platelet-platelet interaction.
The prophylactic effect of the aspirin-ticlopidine combination
was previously tested in the rabbit model of S. aureus IE by Nic-
olau et al [29]. These authors reported a statistically signiﬁcant
decrease in mean vegetation weights in treated animals but no
decrease in valve infections. In contrast, the present results
showed a decrease in both vegetation weights and valve infec-
tions. We postulate that this difference is due to the inoculation
technique used in classical models of experimental IE, in which
animals are infected with intravenous bolus injections of high
bacterial numbers. This results in transient (1–2 minutes) bac-
teremia of >1000 CFU/mL, which may overcome the beneﬁcial
effect of antiplatelet prophylaxis. In contrast, the more realistic
model used here produced bacterial concentrations in the blood
that did not exceed 2–50 CFU/mL but persisted for a prolonged
period [14]. These bacterial concentrations in the blood are
Table 1. Anticoagulant Effect of Dabigatran Etexilate and
Acenocoumarol
Variable
Clotting Time, min, Mean ± SD
Saline
Streptococcus
gordonii
Staphylococcus
aureus
No drug 6.00 ± 0.40 4.50 ± 0.28 3.50 ± 0.28
Dabigatran
etexilate
40.75 ± 2.13a 42.50 ± 10.90a 39.50 ± 2.59a
Acenocoumarol 24.25 ± 2.83a 25.25 ± 5.34a 30.50 ± 4.55a
The anticoagulant effect of dabigatran etexilate and acenocoumarol was
assessed in 3 independent experiments by measuring the clotting time in
the blood of rats 48 hours after the onset of the prophylactic regimen.
a P < .02, by the Student t test, compared with the clotting time in the absence
of drug (no drug).
Figure 4. Efﬁcacy of prophylaxis after anticoagulation with either the
antithrombin dabigatran etexilate (DE) or the vitamin K antagonist aceno-
coumarol (ACC) on both the weight of vegetations (upper panel) and the
prevention of experimental endocarditis (lower panel) due to Staphylococ-
cus aureus. Data on vegetation weights are expressed as mean ± standard
deviation. The numbers of infected animals/total number of animals are
indicated at the bottom of each column. *P < .05, by the Student t test
(for vegetation weight) or the Fisher exact test (for infected vegetations),
compared with the control group.
Figure 3. Efﬁcacy of prophylaxis after anticoagulation with either the
antithrombin dabigatran etexilate (DE) or the vitamin K antagonist aceno-
coumarol (ACC) on both the weight of vegetations (upper panel) and the
prevention of experimental endocarditis (lower panel) due to Streptococcus
gordonii. Data on vegetation weights are expressed as mean ± standard
deviation. The numbers of infected animals/total number of animals are
indicated at the bottom of each column. *P < .05, by the Student t test
(for vegetation weight), compared with the control group.
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comparable to those measured after dental extraction in
humans [5, 6] but are low enough to beneﬁt from antiplatelet
prophylaxis. Indeed, the difference between successful aspirin-
ticlopidine prophylaxis in the setting of continuous low-grade
S. gordonii bacteremia versus transient high-grade bacteremia
was substantiated in a parallel study in which we showed that
this combination did not reduce the incidence of IE in the
bolus inoculation model (data not shown).
Our results also showed that blocking the agonist GPIIb/IIIa
ﬁbrinogen platelet receptor with abciximab [11] afforded effec-
tive protection against both organisms, as well. On the other
hand, eptiﬁbatide, which targets the same receptor, failed
completely. These opposite in vivo results, which occurred de-
spite the fact that both drugs produced a similar antiaggregation
effect (lag time) in vitro, are most likely explained by different
pharmacokinetics and/or different afﬁnity proﬁles for the
GPIIb/IIIa platelet receptor [30]. Eptiﬁbatide is a small mole-
cule with a rapid rate of dissociation from GPIIb/IIIa and
could be rapidly cleared from the system. In contrast, abciximab
is a chimeric Fab fragment monoclonal antibody with greater,
long-lasting afﬁnity for GPIIb/IIIa that almost irreversibly
inhibits the receptor.
S. aureus platelet activation/aggregation occurring via GPIIb/
IIIa depends also on the presence of speciﬁc antibodies and the
low-afﬁnity immunoglobulin G (IgG) platelet receptor FcγRIIa.
For example, anti-ClfA IgG serves as transduction signal for
S. aureus platelet activation, together with a ClfA ﬁbrinogen-
ﬁbrin bridge with GPIIb/IIIa [31]. However, rat platelets do
not express FcγRIIa on their surface, in contrast to human
platelets. This could affect the interaction of S. aureus with rat
platelets and inﬂuence the effect of abciximab. However, the
presence of FcγRIIa on human platelets should not affect the
activity of this compound against S. aureus in humans. Indeed,
even if S. aureus is recognized by anti-ClfA IgG and is attached
to FcγRIIa, abciximab will still be able to block GPIIb/IIIa and
subsequent bacterial-induced platelet activation/aggregation,
because both FcγRIIa and GPIIb/IIIa are necessary to trigger
it [31]. In the case of S. gordonii, the interaction with GPIIb/
IIIa platelet receptor is mediated by PadA without speciﬁc
IgG intervention and independently of the FcγRIIa receptor
[31], and thus the effect of abciximab should be similar in
rats and in humans.
We next tested the antithrombin dabigatran etexilate, which
inhibits ﬁbrinogen-ﬁbrin polymerization promoted by staphy-
lococcal coagulase. Staphylocoagulase binds to prothrombin
to form a proteolytically active complex (staphylothrombin)
that converts ﬁbrinogen into ﬁbrin and facilitates S. aureus–
induced platelet aggregation [32]. Moreover, since dabigatran
etexilate is an anticoagulant, we used acenocoumarol (a vitamin
K antagonist) as a control. Dabigatran etexilate successfully pre-
vented experimental IE due to S. aureus but not due to S. gor-
donii, while acenocoumarol had no effect against any tested
bacteria. Protection of dabigatran etexilate against S. aureus ex-
perimental IE could be associated with the inhibition of ﬁbrin-
ogen-ﬁbrin polymerization by blocking not only thrombin but
also staphylothrombin, which exacerbates ﬁbrin formation [33].
This would decrease platelet–platelet interaction occurring
via GPIIb/IIIa receptor and, likely, also S. aureus–platelet inter-
action in humans. In the case of S. gordonii, the lack of dabiga-
tran etexilate activity could be explained by the fact that this
microorganism is able to induce ﬁbrinogen-ﬁbrin polymeriza-
tion in a thrombin-independent way, using the FSS2 challisin
protein [34].
Taken together, the present results provide clues about how
an antiplatelet or anticoagulant compound could play a role in
the prevention of IE in humans, in addition to the known effect
of such agents on the thrombotic-coagulation system. The prin-
cipal mechanism appeared to be inhibition of platelet activa-
tion, not anticoagulation, as shown by the absence of efﬁcacy
of acenocoumarol.
Nevertheless, we cannot exclude that other additional effects
of the drugs, outside of targeting platelet receptors, could con-
tribute to protect animals from endocarditis. For instance, aspi-
rin may also have a COX1-independent vitamin K antagonism
[35].Moreover, the ability of aspirin to protect the endothelium
from oxidative stress, as well as its demonstrated capacity to
alter the expression of S. aureus virulence factors [36], could
also improve its efﬁcacy. P2Y12 inhibitors as well as GPIIb/
IIIa blockers, such as abciximab, may also have an antiinﬂam-
matory effect [37, 38]. Finally, dabigatran etexilate, by blocking
thrombin, reduced thrombin-induced production of extracellu-
lar matrix proteins and proinﬂammatory factors [39]. Further
investigation is required to clarify the role of these additional
effects in our experimental model.
The question arises as to which antiplatelet or anticoagulant
drug would be the most adequate for the prevention of IE
in humans. The advantage of the combination of aspirin with
ticlopidine (or equivalent newer molecules) over abciximab is
that they can be administered orally for prolonged periods to
decrease the risk of both streptococcal and staphylococcal IE
simultaneously. In contrast, abciximab must be administered
intravenously and serves essentially as a proof of concept unless
user-friendly oral formulations are developed.
Long-term use of aspirin to prevent IE-related embolism has
been a matter of debate [40]. Some authors reported no decrease
in embolic events at the expense of a greater risk of bleeding
[41], whereas others reported a beneﬁcial effect [42]. On this
basis, Eisen and Bayer [40] argued that antiplatelet prevention
of IE should be reevaluated, especially with regard to its most
severe form due to S. aureus, which is responsible for up to
50% of mortality in cases of prosthetic valve IE [9, 43].
Here we also underlined the high preventive efﬁcacy of dabi-
gatran etexilate against S. aureus infection and propose it as an
alternative to anti–vitamin K compounds for anticoagulation in
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patients with prosthetic valves because it would additionally
protect from S. aureus infection. However, a phase 2 study com-
paring dabigatran etexilate to warfarin in prosthetic valve anti-
coagulation [44] was prematurely stopped because of an
increase in thromboembolic events in the dabigatran etexilate
group (http://www.fda.gov/drugs/drugsafety/ucm332912.htm).
Detailed information on these results will be critical before
such compounds can be deﬁnitively excluded from the prophy-
lactic armamentarium.
In conclusion, our study demonstrates the beneﬁcial effect of
both antiplatelet and direct antithrombin drugs in the preven-
tion of experimental endocarditis in a rat model mimicking
spontaneous low-grade bacteremia in humans. These ﬁndings
might have implications in the prophylaxis of IE in patients
with at-risk valve lesions. As suggested by Eisen and Bayer
[40], it might be time to reevaluate the beneﬁcial effect of
these drugs for prevention rather than treatment of IE.
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